Melanie Grace Huber

Array ( [id] => 16688382 [patent_doc_number] => 20210070858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => CD55-Binding Agent-Related Methods and Compositions [patent_app_type] => utility [patent_app_number] => 16/640331 [patent_app_country] => US [patent_app_date] => 2018-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12997 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -76 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16640331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452623 [patent_doc_number] => 20200362049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => CD38 MODULATING ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/638199 [patent_app_country] => US [patent_app_date] => 2018-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25064 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16638199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866305 [patent_doc_number] => 20200140556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => Methods and Compositions for Dectin-2 Stimulation and Cancer Immunotherapy [patent_app_type] => utility [patent_app_number] => 16/626845 [patent_app_country] => US [patent_app_date] => 2018-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40701 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16626845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17569957 [patent_doc_number] => 11318211 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-03 [patent_title] => Dosage regimes for the administration of an anti-CD19 ADC [patent_app_type] => utility [patent_app_number] => 16/622649 [patent_app_country] => US [patent_app_date] => 2018-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 39861 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16622649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15828711 [patent_doc_number] => 20200129637 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE [patent_app_type] => utility [patent_app_number] => 16/605692 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45969 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16605692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15708627 [patent_doc_number] => 20200101079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => ANTICANCER COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 16/500572 [patent_app_country] => US [patent_app_date] => 2018-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16500572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17104383 [patent_doc_number] => 11124579 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-21 [patent_title] => Anti oligosaccharide antibody [patent_app_type] => utility [patent_app_number] => 16/498550 [patent_app_country] => US [patent_app_date] => 2018-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 5991 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15898533 [patent_doc_number] => 20200148785 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => PD-L1 AND TA-MUC1 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/499058 [patent_app_country] => US [patent_app_date] => 2018-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23531 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16499058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15405475 [patent_doc_number] => 20200023059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => ADJUVANT COMPOSITION, AND VACCINE COMPOSITION AND DRUG KIT EACH CONTAINING THE SAME [patent_app_type] => utility [patent_app_number] => 16/497866 [patent_app_country] => US [patent_app_date] => 2018-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16497866 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18232086 [patent_doc_number] => 11596629 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-07 [patent_title] => Compounds and methods for treating cancer [patent_app_type] => utility [patent_app_number] => 16/489133 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 68 [patent_no_of_words] => 15360 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16489133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18273744 [patent_doc_number] => 11612665 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-28 [patent_title] => Pyrrolobenzodiazepine-antibody conjugates [patent_app_type] => utility [patent_app_number] => 16/484342 [patent_app_country] => US [patent_app_date] => 2018-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 36432 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 501 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16484342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14624637 [patent_doc_number] => 20190225686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => ANTI-GPR20 ANTIBODY AND ANTI-GPR20 ANTIBODY-DRUG CONJUGATE [patent_app_type] => utility [patent_app_number] => 16/330085 [patent_app_country] => US [patent_app_date] => 2018-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16330085 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15114659 [patent_doc_number] => 20190343962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => THERAPEUTIC AGENTS TARGETING CLPTM1 [patent_app_type] => utility [patent_app_number] => 16/477389 [patent_app_country] => US [patent_app_date] => 2018-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29529 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16477389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16072425 [patent_doc_number] => 20200190199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => ANTIBODY-DRUG CONJUGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/467655 [patent_app_country] => US [patent_app_date] => 2017-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4816 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16467655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15553585 [patent_doc_number] => 20200061204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => MET ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/346260 [patent_app_country] => US [patent_app_date] => 2017-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14896 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15321133 [patent_doc_number] => 20200000896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => COMPOSITIONS AND METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/348564 [patent_app_country] => US [patent_app_date] => 2017-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7705 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14993815 [patent_doc_number] => 20190315865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => METHODS OF TREATING UROTHELIAL CARCINOMA USING AN ANTI-PD-1 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/345356 [patent_app_country] => US [patent_app_date] => 2017-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18683 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345356 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428418 [patent_doc_number] => 20220056126 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/340855 [patent_app_country] => US [patent_app_date] => 2017-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28948 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16340855 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15405501 [patent_doc_number] => 20200023072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => ANTIBODY-DRUG CONJUGATES WITH IMMUNE-MEDIATED THERAPY AGENTS [patent_app_type] => utility [patent_app_number] => 16/341194 [patent_app_country] => US [patent_app_date] => 2017-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24544 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17307391 [patent_doc_number] => 11208484 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers [patent_app_type] => utility [patent_app_number] => 16/339819 [patent_app_country] => US [patent_app_date] => 2017-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 4544 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16339819 [rel_patent_id] =>[rel_patent_doc_number] =>)